PDF
ePub
Citation
Print
Abstract
Purpose
This study analyzed recent trends of instrument usage assessing cognitive function of breast cancer patients undergoing chemotherapy.
Methods
The researcher collected 64 studies outside the country that were published between January 1996 and August 2010.
Results
There was no study on the instrument assessing all domains of cognitive function in breast cancer patients undergoing chemotherapy. Most instruments assessing cognitive function of breast cancer patients have been used for patients with dementia, depression, and/or organic brain damage. Also the objective neuropsychological tests such as the grooved pegboard for the psychomotor area, RCFT copy in visuospatial skill area and the WAIS-III block design have low sensitivity for measuring cognitive function in breast cancer patients, thus they are not good for applying to breast cancer patients.
Conclusion
There is a need to develop an instrument which has good sensitivity and specificity for measuring the cognitive function of the breast cancer patients who experienced cognitive impairment after chemotherapy treatment. In addition, the developed instrument needs to be accessible and feasible in any nursing clinical setting for the purpose of accurate assessment and evaluation of the cognitive function among breast cancer patients.
Figures and Tables
Table 3
Type and Frequency of Neuropsychologic Tests to Specific Cognitive Domain Function
AVLT, Auditory Verbal Learning Test; CANTAB RVIP, Cambridge Neuropsychological Test Automated Battery Rapid Visual Information Processing; CANTAB SWM, Cambrdge Neuropsychological Test Automated Battery Spatial Working Memory; CANTAB PAL, Cambridge Neuropsychological Test Automated Battery Paired Associate Learning; CANTAB SOC, Cambridge Neuropsychological Test Automated Battery Stockings of Cambridge; COWAT, Controlled Oral Word Association Test; CST, Concept Shifting Test; LDCT, Letter Digit Coding Test; RBMT, Rivermead Behavioral Memory Test; CPT, Continuous Performance Test; CVLT, California Verbal Learning Test; HVLT, Hopkins Verbal Learning Test; HVLT-R, Hopkins Verbal Learning Test-Revised; PASAT, Paced Auditory Serial Addition Test; RAVLT, Rey Auditory Verbal Learning test; RCFT, ReyOsterrieth Complex Figure Test; CWIT, Color Word Interference Test; RWFT, Resenberg Word Fluency Test; SCWIT, Stroop Color Word Interference Test; WAIS, Wechsler Adult Intelligence Scale; VSRT, Verbal Selective Reminding Test; WCST, Wisconsin Card Sorting Test; WRAT, Wide Range Achievement Test; WMS, Wechsler Memory Scale.
References
1. Weiss B. Evaluation of multiple neurotoxic outcomes in cancer chemotherapy. Adv Exp Med Biol. 2010. 678:96–112.
2. Biglia N, Moggio G, Peano E, Sgandurra P, Ponzone R, Nappi RE, et al. Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med. 2010. 7:1891–1900.
3. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska K, et al. Cognitive impairment associated with adjuvant therapy in women with breast cancer. Psychooncology. 2006. 15:422–430.
4. Hermelink K, Untch M, Lux MP. Cognitive function during neoadjuvant chemotherapy for breast cancer: Results of a prospective, multicenter, longitudinal study. Cancer. 2007. 109:1905–1913.
5. Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficit: Mechanisms, findings, and potential interventions. Palliat Support Care. 2007. 5:273–280.
6. Stewart A, Collins B, Mackenzie J. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: A prospective study. Psychooncology. 2008. 17:122–130.
7. Rottok J, Ross B. Cognitive rehabilitation. 1994. Washington DC: American Psychiatric Press.
8. Kim SH. Effects of individualized exercise program on cancer-related fatigue, physical and cognitive function, and emotional status in patients with gastric cancer during chemotherapy [dissertation]. 2005. Seoul: Yonsei Univ..
9. Matsuda T, Takayama T, Tashioro M, Nakamura Y, Ohash Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005. 12:279–287.
10. Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 2008. 17:1189–1195.
11. Van Dam FS, Schagen SB, Muller MJ, Boogerd W, Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998. 90:210–218.
12. Schagen SB, Enny D, Frits SA, Van Dam FS. The influence of priming and pre-existing knowledge of chemotherapy associated cognitive complaints breast cancer patients. Psychooncology. 2009. 18:674–678.
13. Choi EH, Chung BY, Kim GD, Kim KH, Byun HS. Literature review of cognitive developmental interventions on patients with breast cancer undergoing chemotherapy. J Korean Oncol Nurs. 2011. 11:26–32.
14. Kim DY, Kim IS, Kim TY, Park RJ, Park JM, Son GC, et al. Prevention of dementia and cognitive rehabilitation program. 2004. Seoul: Seohyunsa.
15. Jansen CE, Miaskowski CA, Dodd MJ, Dowling GA. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncol Nurs Forum. 2007. 34:997–1005.
16. Cimprich B, SO H, Roni DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005. 14:70–78.
17. Cimprich B. Attentional fatigue following breast cancer surgery. Res Nurs Health. 1992. 15:199–207.
18. Aaronson NK, Ahmedzai S, Bergman B. The european organization for research and treatment of cancer QOL-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993. 85:365–376.
19. Functional Assessment of Cancer Therapy-Cognitive function version 3. accessed on 1 December 2010. Available at: http://www.facit.org/FACITOrg/Questionnaires.
20. Faust D, Fogel BS. The development and initial validation of sensitivity bedside cognitive screening test. J Nerv Ment Dis. 1989. 177:25–31.
21. Broadbent DE, Cooper PF, Fitz Gerald P, Parkes KR. The cognitive failures questionnaire(CFQ) and its correlates. Br J Clin Psychol. 1982. 21:1–16.
22. Huyser Y. De symptomatologie van depressieve stoornissen en angststoornissen. 1993. Amsterdam: Beneckee Consultants.
23. Schagen SB, Muller MJ, Boogerd W. Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clin Breast Cancer. 2002. 3:S100–S108.
24. Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: What are the tools? Clin Breast Cancer. 2002. 3:S91–S99.
25. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trail. Cancer. 2004. 100:2292–2299.
26. Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatment on cognition in women with early stage breast cancer. Br J Cancer. 2006. 94:828–834.
27. Shilling V, Jenkis V. Self reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007. 11:6–15.
28. Park JH, Kim HC, Lee YH, Lee JH. Revised cognitive impairment diagnosing instrument(CIDI): A semi-structured interview form for assessment of cognitive functions. J Korean Neuropsychiatr Assoc. 2000. 39:589–597.
29. Shulman KI. Clock-drawing: Is this the ideal cognitive screening test? Int J Geriatr Psychiatry. 2000. 15:548–561.
30. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004. 26:955–969.
XML Download